This project will clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of primary ovarian failure (POF) patients and provide a new therapeutic method for patients with infertility.

POF is a defect characterized by the premature depletion of ovarian follicles. Patients with POF suffer from amenorrhea, infertility, low levels of estrogen, and high gonadotropin concentration before the age of 40. The early failure of ovarian function leads to lost fertility and increases risk of osteoporosis and cardiovascular disease, which has serious impact on the patient's physical, mental health and family stability. The etiology of POF is complex, and so far there has not been any effective treatment. Recent study showed that human amniotic epithelial cells (hAECs), also known as the birth waste, are newly discovered adult stem cells. The hAECs have the ability to repair nerve damage, myocardial injury, as well as liver damage. hAECs have low immunogenicity and no ethical restrictions. Therefore, hAECs are expected to become the new seed cells for regenerative medicine. Our previous study was the first to show that human amniotic epithelial cells have the ability to restore folliculogenesis in a mouse model with chemotherapy-induced premature ovarian failure. Our further studies demonstrated that hAECs either directly transdifferentiated into granulosa cells, or inhibited tumor necrosis factor-alpha-mediated granulosa cell apoptosis and reduced the inflammatory reaction in ovaries induced by chemotherapeutics, regulating VEGFA and its receptors to induce follicular growth related to paracrine activity. Therefore, it is necessary to start the clinical study of human amniotic epithelial cells transplantation in the POF disease which may offer a novel therapeutic strategy for improving the quality of life of POF patients.

Inclusion Criteria:

1. ≥18 and<45 years old.
2. Female patients with documented diagnosis of POF: <40 years old, at least 4 months of amenorrhea not due to pregnancy, two FSH levels above 40 IU/L, at least one month apart.
3. Not in other trial within 3 months prior to the start of this trial.
4. Willing to participate in this trial and to give informed consent/assent before any procedures are performed in this trial.

Exclusion Criteria:

1. History of, or evidence of current malignancy within the past 5 years.
2. Severe functional impairment of vital organs.
3. Abnormal karyotype.
4. Coagulation disorders.
5. Severe pelvic adhesions.
6. Uncontrolled acute or chronic gynecologic inflammation.
7. Congenital adrenal cortical hyperplasia.
8. Cushing's syndrome.
9. Thyroid dysfunction.
10. Pituitary adenoma.
11. Pituitary amenorrhea or Hypothalamic amenorrhea.
12. Thrombophlebitis, venous thrombosis or artery thrombosis.
13. History of Oophorocystectomy.
14. Currently pregnant or breast-feeding.
15. Currently receiving other treatment that might affect the efficacy and safety of stem cells.
16. History of severe drug allergy.
17. Active infection detected by chest X-ray/CT.
18. HIV, TPAb positive.
19. Mental illness.
20. Currently participating in any other clinical trial that uses interventional drugs or examinations.
21. Patients that are deemed, by the investigator, inappropriate to participate in this trial.

The public can require the data and protocol from clinicaltrials.gov posted by investigator

2 years

public